feedback welcome

Dosulepine-citalopram

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[checked revision][draft revision]
 
Line 3: Line 3:
| to = citalopram  
| to = citalopram  
| stop =  
| stop =  
-
* '''Before day 1:''' gradually reduce dosage of dosulepine to a maximum of 75 mg/day.
+
{{stopDosulepine}}
-
* '''Day 1:''' reduce dosage of dosulepine to 50 mg/day.
+
-
* '''Day 3:''' reduce dosage of dosulepine to 25 mg/day.
+
-
* '''Day 7:''' stop dosulepine
+
| start =  
| start =  
-
* '''Day 8:''' start administration of citalopram in a normal dosage of 20 mg/day.
+
* '''Day 9:''' start administration of citalopram in a normal dosage of 20 mg/day.
| info =  
| info =  
-
* Occurrence of serotonin syndrome is theoretically possible, so caution is necessary.
+
* {{theorSS}}
* Citalopram is a weak inhibitor of CYP2D6, which metabolizes dosulepine.   
* Citalopram is a weak inhibitor of CYP2D6, which metabolizes dosulepine.   
-
{{review}}
 
}}
}}

Current revision as of 12:07, 2 November 2015

dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin
Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram

Switch medication from dosulepine to citalopram.

Nietinrijdenbord.png Stop dosulepine
Eenrichtingbord.png Start citalopram
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About